Abstract
Critically ill patients with COVID-19 face a higher risk of disease progression and complications. The current standard of care includes supportive care measures and fluid management. The Recovery trial observed a reduction in all-cause, 28-day mortality (p<0.001) when patients with COVID-19 requiring oxygen therapy received 6 mg of dexamethasone per day for 10 days. In contrast, in patients not requiring oxygen, no benefit was observed: 28-day mortality rates for the dexamethasone and routine care groups were 17.8% and 14%, respectively. To corroborate these results, the World Health Organization (WHO) performed a meta-analysis. The study showed that the use of systemic corticosteroids compared with routine care placebo was associated with a decrease in all-cause, 28-day mortality. With respect to the effectiveness of remdesivir, the ACTT-1 trial found that the drug conferred a benefit on time to clinical improvement. The subgroup analysis in the clinical trial also showed a benefit per mortality in patients requiring supplemental oxygen, albeit not those in need of mechanical ventilation.
【초록키워드】 Dexamethasone, Meta-analysis, Corticosteroids, clinical trial, Mortality, Trial, mechanical ventilation, 28-day mortality, Remdesivir, oxygen, drug, Disease progression, Critically ill, Patient, Effectiveness, Oxygen therapy, Clinical improvement, complications, WHO, Placebo, group, RECOVERY trial, critically ill patients, supportive care, Health Organization, World Health Organization, Standard of care, Critically ill patient, supplemental oxygen, higher risk, systemic corticosteroids, measure, subgroup analysis, routine care, benefit, decrease, Fluid management, performed, include, per day, reduction in, patients with COVID-19, requiring supplemental oxygen, systemic corticosteroid, with COVID-19, 【제목키워드】 SARS-CoV-2, Antiviral treatment, steroid therapy, indication,